Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transfusion ; 57(8): 1922-1929, 2017 08.
Article in English | MEDLINE | ID: mdl-28518220

ABSTRACT

BACKGROUND: Iron deficiency represents a risk to donor health and the blood supply. Efficacy trials indicate that postdonation iron replacement improves iron stores but they do not account for complexities of implementation in the routine collection context. We therefore conducted two prospective feasibility studies in Australian donor centers. STUDY DESIGN AND METHODS: In both studies we recruited female donors between 18 and 45 years who had made at least one donation in the previous 12 months. In READ (replacement advice), female donors were given a recommendation to self-procure postdonation iron. In DIRECT (donor iron replacement), donors were provided with a course of iron supplements. Donors could return to donate at their discretion and were surveyed after the recruitment visit and again toward the end of the 13-month follow-up. Donor uptake, adverse effects, effectiveness in maintaining iron stores, and workflow impact were assessed. RESULTS: We recruited 1404 (70.9% of invited) donors to READ and 768 (53.2% of invited) to DIRECT. READ and DIRECT extended predonation interviews by 1 and 5 minutes, respectively. Among participants, 44 and 88% took iron in READ and DIRECT, respectively. Adverse effects were common but usually mild. READ failed to maintain iron stores in the population, but was effective in donors who consumed more than 75% of the recommended dose. DIRECT was effective in preventing declines in ferritin concentration. CONCLUSION: Trade-offs between cost, complexity, uptake, and effectiveness must be considered in the implementation of postdonation iron supplementation.


Subject(s)
Blood Donors , Iron/therapeutic use , Adolescent , Adult , Australia , Dietary Supplements/adverse effects , Dietary Supplements/economics , Feasibility Studies , Ferritins/blood , Humans , Iron/adverse effects , Iron/pharmacokinetics , Middle Aged , Surveys and Questionnaires , Young Adult
2.
Transfus Apher Sci ; 53(3): 404-11, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26626963

ABSTRACT

BACKGROUND: This research examined the effect of autologous serum eye drops (ASED) on ocular symptoms, visual-related functioning and quality of life for patients failing other therapies. METHODS: Patients (N = 77) were asked to complete a survey prior to ASED use, and 2 and 12 months post-treatment. RESULTS: Significant improvements in symptom frequency and severity were documented for dryness, ocular pain and grittiness at 2 and 12 months. Patients felt more in control and required less help from others at 12 months. CONCLUSIONS: ASED produce sustained benefits to dry eye symptoms, improve feelings of control and reduce requirements for assistance from others.


Subject(s)
Corneal Diseases/drug therapy , Dry Eye Syndromes/drug therapy , Ophthalmic Solutions/therapeutic use , Quality of Life , Serum , Vision, Ocular/drug effects , Adult , Aged , Australia , Epithelium, Corneal/metabolism , Epithelium, Corneal/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged
3.
Transfusion ; 54(3 Pt 2): 780-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24660763

ABSTRACT

BACKGROUND: Blood donation is known to contribute to iron deficiency in regular blood donors. This study investigated the safety and efficacy of postdonation iron replacement to mitigate iron deficiency in blood donors. STUDY DESIGN AND METHODS: A total of 282 female whole blood donors aged 18 to 45 were prospectively randomized in a double-blinded placebo controlled trial to receive an 8-week postdonation course of carbonyl iron (45 mg daily) or placebo. The primary endpoint was prevalence of iron deficiency (ferritin < 15 ng/mL) at 12 weeks postdonation. Secondary endpoints were eligibility to donate based on capillary hemoglobin (Hb) and incidence of gastrointestinal (GI) complaints. RESULTS: Ferritin levels at Week 12 were significantly higher in donors receiving carbonyl iron (17.0 ± 10.9 ng/mL) compared with those receiving placebo (10.6 ± 8.4 ng/mL; p < 0.001). The proportion of iron-deficient donors was significantly lower in the carbonyl iron group (51.9%) compared to the placebo (80.5%; p < 0.001). The mean Hb level in the carbonyl iron group (134.6 ± 8.7 g/L) was significantly higher than in the placebo arm (130.0 ± 9.9 g/L; p < 0.001), significantly improving eligibility to donate at Week 12. Significantly more donors receiving carbonyl iron had at least one GI side effect (p < 0.001). Importantly, 86.7% of donors receiving carbonyl iron indicated that they would take iron on an ongoing basis. CONCLUSION: An 8-week postdonation course of 45 mg of carbonyl iron significantly reduced iron deficiency and was well tolerated in female whole blood donors. Postdonation iron replacement may have a role in a broader strategy to optimize donor iron status.


Subject(s)
Anemia, Iron-Deficiency/drug therapy , Iron Compounds/therapeutic use , Iron/blood , Adolescent , Adult , Anemia, Iron-Deficiency/blood , Double Bind Interaction , Drug Administration Schedule , Female , Ferritins/blood , Humans , Middle Aged , Prospective Studies , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...